Table 2.
Demographic and neuropsychological characteristics
| Non‐hallucinators | Hallucinators | P value | |
|---|---|---|---|
| Number | 13 | 9 | |
| Age | 61.5 ± 5.5 | 65.7 ± 4.1 | ns |
| Disease duration (years) | 4.9 ± 2.9 | 6.7 ± 3.2 | ns |
| UPDRS IIIa | 21.1 ± 9.1 | 27.6 ± 14.2 | ns |
| Hoehn and Yahr, stage | 2.1 ± 0.4 | 2.1 ± 0.2 | ns |
| Dopa dose equiv, mg/daya | 1264.0 ± 517 | 1081.9 ± 680 | ns |
| BDI‐IIa | 8.0 ± 7.4 | 9.2 ± 6.1 | ns |
| MoCA | 27.1 ± 2.1 | 26.7 ± 2.1 | ns |
| TMTB‐A a | 48.5 ± 47.6 | 89.6 ± 29.8 | < 0.05 |
| SCOPA‐PC1‐4 a | 0.5 ± 0.7 | 2.6 ± 1.9 | < 0.01 |
| RBD‐Qa | 4.5 ± 3.7 | 7.4 ± 2.2 | < 0.05 |
| BPP error score (%)a | 9.1 ± 3.8 | 19.4 ± 6.8 | < 0.05 |
| Contrast sensitivity | 1.69 ± 0.0 | 1.60 ± 0.0 | ns |
UPDRS, Unified Parkinson's Disease Rating Scale; BDI, Beck's Depression Inventory; MoCA, Montreal Cognitive Assessment; TMTB‐A, Trail Making Test: Part B minus Part A; RBD‐Q, Rapid Eye Movement Behavior Disorder Questionnaire; BPP, Bistable Percept Paradigm.
a
t‐Test with unequal variance.